Company news
Alpha Cognition Inc. (NASDAQ:ACOG) news
Every Alpha Cognition Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
August 17, 2026
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
August 13, 2026
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
August 3, 2026
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease
July 29, 2026
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
July 10, 2026
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
June 23, 2026
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease
June 16, 2026
Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer’s Disease
June 9, 2026
Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update
May 14, 2026
Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
April 28, 2026
Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
April 27, 2026
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
April 20, 2026
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2026
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
April 1, 2026
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
March 26, 2026
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026
March 13, 2026
Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International Conferences
March 10, 2026
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
February 25, 2026
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens
February 18, 2026
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
January 7, 2026
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners
December 1, 2025
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
November 13, 2025
Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
October 30, 2025
Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference
October 15, 2025
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
October 14, 2025
Alpha Cognition to Present Clinical Data at ASCP Annual Meeting
October 6, 2025
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
September 30, 2025
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
September 30, 2025
Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
August 28, 2025
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
August 14, 2025
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
August 4, 2025
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
July 29, 2025
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
July 8, 2025
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
July 1, 2025
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
May 15, 2025
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
May 1, 2025
Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
April 30, 2025
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
April 28, 2025
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
April 10, 2025
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
March 31, 2025
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
March 31, 2025
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
March 19, 2025
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
March 18, 2025
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
February 12, 2025
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
January 14, 2025
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
January 8, 2025
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
January 6, 2025
Alpha Cognition Announces Partial Exercise of Over-allotment Option
December 16, 2024
Alpha Cognition Announces Voluntary Delisting from CSE
December 12, 2024
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
December 11, 2024